Bluepoint Partners Secures 10 Billion Won in Investment

Deep tech accelerator Bluepoint Partners announced on the 22nd that it has secured 10 billion won in investment to enhance its initial investment.

This investment round involved Jet Venture Capital (ZVC) and global healthcare company InBody, each contributing 5 billion won. The company's valuation for the investment round was undisclosed. ZVC is the corporate venture capital (CVC) arm of LY Corporation, a subsidiary of A Holdings, a joint venture between Naver and SoftBank.

Bluepoint plans to use the secured investment funds to discover globally competitive startups and strengthen its technology commercialization process. This investment is significant beyond simple funding, as it also strengthens strategic partnerships. Bluepoint aims to maximize synergy with ZVC and InBody by leveraging its technological expertise and commercialization capabilities.

ZVC leverages its networks in Japan and the US to provide a global testbed for Bluepoint's investment portfolio and participates in the discovery and collaboration of domestic deep-tech startups. Together with InBody, the company accelerates innovation in industries including bio and healthcare through a startup approach, leveraging its technological prowess and infrastructure to support market exploration and growth.

Bluepoint is currently collaborating with LG Electronics, LG Uplus, HD Hyundai Electric, and POSCO Holdings, based on its investment experience in deep tech fields with high technological difficulty, such as nuclear fusion, quantum computing, and defense AI.

ZVC CEO Hwang In-jun stated, "Bluepoint is the optimal partner with a unique position in the deep tech sector. This investment will serve as a catalyst for our continued support of Korean technology companies' global growth." Bluepoint CEO Lee Yong-kwan stated, "This round of funding has once again recognized Bluepoint's investment expertise. Together with global companies, we will drive the global expansion of Korean deep tech startups."

• See more related articles